-
Mitchell Smith, MD, PhD; GW Cancer Center; 5Live #ASH20
5:20
Key insights from the 2020 Annual Hematology meeting in Lymphoma
-
Paolo Strati, MD; University of Texas MD Anderson Cancer Center 5Live #ASCO20
5:45
Key insights on Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel).
-
Nirav Niranjan Shah, MD, MS Medical College of Wisconsin 5Live #ASCO20
4:51
Key Insights on Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.
-
Charles Herbaux, MD, MSc Centre Hospitalier Regional Universitaire de Lille, France 5Live #ASCO20
5:36
Key Insights on Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.
